Company: Lyell Immunopharma Inc.
Job title: Cancer immunotherapy Explorer
Enhancing Stemness of Polyclonal T Cells to Improve Anti-Tumor Activity 9:30 am
• Yielding highly effective polyclonal T cell products by utilizing next generation strategies including gene editing • Enriching for tumor-specific T cell clonotypes in clinical T cell products to improve therapeutic efficacy • Emerging approaches to maximize clinical utility of TIL productsRead more
day: Day One